Search Results - "Remer, Marcus"

Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function by Buchan, Sarah L., Dou, Lang, Remer, Marcus, Booth, Steven G., Dunn, Stuart N., Lai, Chester, Semmrich, Monika, Teige, Ingrid, Mårtensson, Linda, Penfold, Christine A., Chan, H.T. Claude, Willoughby, Jane E., Mockridge, C. Ian, Dahal, Lekh N., Cleary, Kirstie L.S., James, Sonya, Rogel, Anne, Kannisto, Päivi, Jernetz, Mats, Williams, Emily L., Healy, Eugene, Verbeek, J. Sjef, Johnson, Peter W.M., Frendéus, Björn, Cragg, Mark S., Glennie, Martin J., Gray, Juliet C., Al-Shamkhani, Aymen, Beers, Stephen A.

“…The costimulatory receptor 4-1BB is expressed on activated immune cells, including activated T cells. Antibodies targeting 4-1BB enhance the proliferation and…”
Get full text

Cancer Immunotherapy by Targeting 4-1bb with Immunostimulatory Antibodies by Remer, Marcus

“…4-1BB (CD137) is a T cell activating receptor belonging to the TNF receptor superfamily that can betargeted by mAb to eradicate established tumours. 4-1BB is…”
Get full text

Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas by Remer, Marcus, Al-Shamkhani, Aymen, Glennie, Martin, Johnson, Peter

“…Glyco-engineering has been developed to enhance the pharmacological properties of monoclonal antibodies (mAbs) resulting in superior immune effector function…”
Get more information

Immunotherapy in metastatic melanoma: When is it safe to stop? by Longley, Jemma, Paschalis (co-first author), Alec, Remer, Marcus, Bennett, James, Muller, Daniel R, Stone, Ruth, Karydis, Ioannis, Donnelly, Oliver, Ottensmeier, Christian H.H, Wheater, Matthew James

“…Abstract only…”
Get full text

The Use of Anti-CD40 mAb in Cancer by Remer, Marcus, White, Ann, Glennie, Martin, Al-Shamkhani, Aymen, Johnson, Peter

“…Immunomodulatory monoclonal antibody (mAb) therapy is at the forefront of developing cancer therapeutics with numerous targeted agents proving highly effective…”
Get more information

Risk- and response-adapted strategies for the management of Hodgkin lymphoma by Remer, Marcus, Johnson, Peter W M

“…Therapy for Hodgkin lymphoma (HL) is associated with excellent long-term survival rates, of 80% of more. Extended follow up has described late…”
Get more information